A Study of Perturbation of Human Small Intestinal Colonic Permeability

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

May 23, 2024

Study Completion Date

July 31, 2024

Conditions

Healthy

Interventions

DIETARY_SUPPLEMENT

Ricinoleic Acid 750 mg

750 mg administered orally

DIETARY_SUPPLEMENT

Ricinoleic Acid 1500 mg

1500 mg administered orally

DIETARY_SUPPLEMENT

Ricinoleic Acid 3000 mg

3000 mg administered orally

DRUG

Placebo

Contains no active ingredient.

Trial Locations (1)

Mayo Clinic Minnesota, Rochester